Clinical Trial: BMN 110 US Expanded Access Program
Study Status: Approved for marketing
Recruit Status: Approved for marketing
Study Type: Expanded Access
Official Title: A Multicenter, Open-label BMN 110 US Expanded Access Program (BMN 110 US EAP) to Provide BMN 110 to Patients Diagnosed With MPS IVA
Brief Summary:
The Expanded Access Program (EAP) is an open-label, multicenter program to:
- Provide patients who have been diagnosed with Mucopolysaccharidosis IVA (MPS IVA) access to BMN 110 until commercial product is available
- Collect additional information on the safety and tolerability of BMN 110 administration in patients with MPS IVA
Patients enrolled in the EAP will receive 2.0 mg/kg intravenous infusions of BMN 110 every week during the program.
Detailed Summary:
Sponsor: BioMarin Pharmaceutical
Current Primary Outcome:
Original Primary Outcome:
Current Secondary Outcome:
Original Secondary Outcome:
Information By: BioMarin Pharmaceutical
Dates:
Date Received: May 15, 2013
Date Started:
Date Completion:
Last Updated: March 31, 2014
Last Verified: March 2014
